Thursday, September 3rd, 2009
Although Amgen and Wyeth were the two major sponsors behind yesterday’s Addressing Psoriasis Fashion Show in New York City, the event itself carefully avoided any direct reference to the companies’ psoriasis drug Enbrel. Hosted by television host and fashion consultant Tim Gunn, the fashion show was designed to recognize people ...
Posted in
Patient education |
No Comments »
Wednesday, March 11th, 2009
The fallout from the Supreme Court's Wyeth v. Levine decision will be added burden not just for pharmaceutical manufacturers, but FDA as well, according to Gary Liberson and Craig Wylie in PA Consulting's Life Sciences & Healthcare practice. Pharmaceutical marketers will be burdened to meet individual State product care laws. ...
Posted in
Sales & Marketing |
No Comments »
Wednesday, March 4th, 2009
With the pharmaceutical industry's effort to enshrine federal FDA pre-emption in the laws of the land taking a tumble after today's Supreme Court ruling in Wyeth v. Levine, mass torts plaintiffs attorneys everywhere are licking their lips. We asked Will Sachse, a partner in the antitrust/competition and mass torts and ...
Posted in
Legal actions |
2 Comments »
Wednesday, March 4th, 2009
The pre-emption question has been answered. But it wasn't what Wyeth or the rest of the pharma industry wanted to hear.
As part of our Agenda 2009 report in January, we reported on the U.S. Supreme Court case Wyeth v. Levine, which asked the judges to decide whether federal regulations governing ...
Posted in
Legal actions, Sales & Marketing |
1 Comment »
Wednesday, March 4th, 2009
When you look good, you feel good. Clothes make the man. Etc. etc. It’s undeniable that the way we dress says a lot about who we are and the impressions we make. So when someone’s health has an impact on their clothing choices, it’s not hard to imagine them suffering ...
Posted in
Sales & Marketing |
No Comments »
Friday, January 30th, 2009
Bill Cooney of MedPoint Communications, another frequent contributor to Med Ad News, has shared with us some of his thoughts on Pfizer's planned acquisition of Wyeth.
The Pfizer/Wyeth deal is not only a milestone on its own merits, but it’s even more important as the opening bell for an historic round ...
Posted in
Pharma Business |
1 Comment »
Monday, January 26th, 2009
Mike Luby, co-founder, TargetRx, is a frequent contributor to Med Ad News. I have always found his perspective, as a long-time industry observer, to be invaluable. I asked him to offer his take on Pfizer’s plan to acquire Wyeth, particularly from a sales and marketing perspective.
Does Wyeth offer any marketing ...
Posted in
Pharma Business |
No Comments »
Monday, January 26th, 2009
So, the numbers are in. CNN reports that Pfizer is planning two waves of job cuts for 2009, first cutting 10% of its 81,900 staff. The second round of cuts will take place after the merger with Wyeth is completed in the third or fourth quarter. This is expected to ...
Posted in
Pharma Business |
No Comments »
Monday, January 26th, 2009
The fourth quarter of 2008 was bleak for Pfizer, which was destined to lose its industry-leading position within the next five years. With the planned acquisition of Wyeth, however, Pfizer should stay on top a while longer.
For the fourth quarter , Pfizer posted reported net income of $266 million, a ...
Posted in
Pharma Business |
No Comments »
Monday, January 26th, 2009
Back in February of 2007, I wrote an article in Med Ad News about the history and potential drawbacks of pharmaceutical megamergers ("For richer or poorer"). This past weekend brought the latest chapter in that saga, with the board of Wyeth accepting a $68 billion cash/stock acquisition offer from Pfizer. ...
Posted in
Pharma Business |
1 Comment »
|
|
